Pfizer and BioNTech have requested the FDA to alleviate requirements for their vaccine to be stored at ultra-low temperatures. Approval may ease distribution in lower-income countries.The companies have submitted new temperature data to support an update to the current label that would allow vials to be stored at -25 to -15 degrees Celsius for a total of two weeks. The current label requires temperatures between -80ºC and -60ºC, meaning it has to be shipped in specially designed containers.If approved, the less onerous storage requirements would provide significant logistical relief.Moderna’s product, which like Pfizer’s is based on so-called messenger RNA molecules, is already cleared for storage at -25 to -15 degrees Celsius.Comments Read Next1 hour agoUAE: Travel agency shut for arranging COVID-19 tests on WhatsApp2 hours agoStudy: AstraZeneca more effective with longer dose gap3 hours agoSaudi Arabia sends relief to South Africa3 hours agoUAE reports 3,140 new Covid-19 cases, 20 deaths3 hours agoUAE: Drones used in Covid-19 awareness campaign11 hours...read more...
